Veramyst is a drug owned by Glaxosmithkline. It is protected by 8 US drug patents filed from 2013 to 2016. Out of these, 4 drug patents are active and 4 have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Apr 01, 2027. Details of Veramyst's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US8347879 | Fluid dispensing device |
Apr, 2027
(2 years from now) | Active |
| US8062264 | Fluid dispensing device |
Apr, 2026
(1 year, 3 months from now) | Active |
| US8752543 | Fluid dispensing device |
Apr, 2026
(1 year, 3 months from now) | Active |
| US8147461 | Fluid dispensing device |
Mar, 2025
(2 months from now) | Active |
| US9320862 | Fluid dispensing device |
Nov, 2024
(a month ago) |
Expired
|
| US7541350 | Formulation containing anti-inflammatory androstane derivative |
Aug, 2021
(3 years ago) |
Expired
|
| US6858596 | Formulation containing anti-inflammatory androstane derivative |
Aug, 2021
(3 years ago) |
Expired
|
| US7101866 | Anti-inflammatory androstane derivative |
Aug, 2021
(3 years ago) |
Expired
|
US patents provide insights into the exclusivity only within the United States, but Veramyst is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Veramyst's family patents as well as insights into ongoing legal events on those patents.
Veramyst's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Veramyst's generic launch date based on the expiry of its last outstanding patent is estimated to be Apr 01, 2027 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Veramyst Generics:
There are no approved generic versions for Veramyst as of now.
Alternative Brands for Veramyst
Veramyst which is used for relieving symptoms of seasonal and perennial allergic rhinitis in patients 2 years of age and older., has several other brand drugs using the same active ingredient (Fluticasone Furoate). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | ||
|---|---|---|---|
| Glaxo Grp Ltd |
| ||
| Glaxosmithkline |
| ||
| Haleon Us Holdings |
|
About Veramyst
Veramyst is a drug owned by Glaxosmithkline. It is used for relieving symptoms of seasonal and perennial allergic rhinitis in patients 2 years of age and older. Veramyst uses Fluticasone Furoate as an active ingredient. Veramyst was launched by Glaxosmithkline in 2007.
Approval Date:
Veramyst was approved by FDA for market use on 27 April, 2007.
Active Ingredient:
Veramyst uses Fluticasone Furoate as the active ingredient. Check out other Drugs and Companies using Fluticasone Furoate ingredient
Treatment:
Veramyst is used for relieving symptoms of seasonal and perennial allergic rhinitis in patients 2 years of age and older.
Dosage:
Veramyst is available in spray, metered form for nasal use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 0.0275MG/INH | SPRAY, METERED | Prescription | NASAL |